Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Structural proteomics in drug discovery.

Leslie W Tari1, Martin Rosenberg, Anthony B Schryvers

  • 1ActiveSight, 4045 Sorrento Valley Blvd, San Diego, CA 92121, USA. ltari@active-sight.com

Expert Review of Proteomics
|August 16, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolism and excretion pathways of CD388, a novel drug-fragment crystallizable conjugate for prevention of seasonal or pandemic influenza.

Drug metabolism and disposition: the biological fate of chemicals·2026
Same author

Rationally designed minimized TbpB confers broad protection against meningococcal infection.

bioRxiv : the preprint server for biology·2025
Same author

Structure-based engineering of a nutrient acquisition protein enhances neutralizing antibodies and protection for the development of a gonococcal vaccine.

bioRxiv : the preprint server for biology·2025
Same author

Drug-Fc conjugate CD388 targets influenza virus neuraminidase and is broadly protective in mice.

Nature microbiology·2025
Same author

Rational selection of TbpB variants yields a bivalent vaccine with broad coverage against Neisseria gonorrhoeae.

NPJ vaccines·2025
Same author

How prevalent are lactoferrin receptors in Gram-negative bacteria?

Biochemistry and cell biology = Biochimie et biologie cellulaire·2025
Same journal

Unveiling the post translational modification code in Alzheimer's pathogenesis: crosstalk between phosphorylation and acetylation.

Expert review of proteomics·2026
Same journal

Plasma proteome profiles of standard-risk and high-risk childhood acute lymphoblastic leukemia.

Expert review of proteomics·2026
Same journal

Potential proteomic biomarkers for monitoring clinical studies in Duchenne/Becker muscular dystrophy.

Expert review of proteomics·2026
Same journal

Proteomics-based approaches to neutrophil biology.

Expert review of proteomics·2026
Same journal

Deciphering mitochondrial metabolic vulnerabilities in ovarian clear cell carcinoma with mass spectrometry-based clinical proteomics.

Expert review of proteomics·2026
Same journal

The proteomic origin of the genetic code.

Expert review of proteomics·2026
See all related articles

High-throughput protein structure determination accelerates drug discovery. This advances structure-based drug design, streamlining lead compound identification and optimization for potential therapeutics.

Area of Science:

  • Biochemistry
  • Structural Biology
  • Pharmacology

Background:

  • High-throughput methodologies are revolutionizing protein structure acquisition.
  • X-ray crystallography is a key technique for obtaining structural information.

Purpose of the Study:

  • To highlight the impact of automated structural biology on drug design.
  • To discuss the challenges and future directions in structure-based drug discovery.

Main Methods:

  • Utilizing high-throughput, automated, and semi-automated methods for protein structure determination.
  • Applying X-ray crystallography to generate protein structural data.

Main Results:

  • Accelerated acquisition of structural information for pharmacologically relevant proteins.

Related Experiment Videos

  • Enabled broader application of structure-based drug design to new targets.

    • Conclusions:

    • Continued development of structure-based drug design methodologies will overcome current hurdles.
    • Increased protein structure data will streamline lead compound identification and optimization.
    • Addressing drug approval process costs and complexity is crucial for future drug development.